155 related articles for article (PubMed ID: 16753589)
21. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis.
Espinosa I; Catasus L; Canet B; D'Angelo E; Muñoz J; Prat J
Mod Pathol; 2011 Jun; 24(6):846-54. PubMed ID: 21317880
[TBL] [Abstract][Full Text] [Related]
22. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
Gilks CB; Vanderhyden BC; Zhu S; van de Rijn M; Longacre TA
Gynecol Oncol; 2005 Mar; 96(3):684-94. PubMed ID: 15721412
[TBL] [Abstract][Full Text] [Related]
23. Genome-wide analysis of deoxyribonucleic acid in endometrial cancer using comparative genomic hybridization microarrays.
O'Toole SA; Dunn E; Sheppard BL; Klocker H; Bektic J; Smyth P; Martin C; Sheils O; O'Leary JJ
Int J Gynecol Cancer; 2006; 16(2):834-42. PubMed ID: 16681770
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
[TBL] [Abstract][Full Text] [Related]
25. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas.
Têtu B; Popa I; Bairati I; L'Esperance S; Bachvarova M; Plante M; Harel F; Bachvarov D
Mod Pathol; 2008 Aug; 21(8):1002-10. PubMed ID: 18500265
[TBL] [Abstract][Full Text] [Related]
27. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
[TBL] [Abstract][Full Text] [Related]
29. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
[TBL] [Abstract][Full Text] [Related]
30. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
[TBL] [Abstract][Full Text] [Related]
31. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
Nakayama K; Nakayama N; Kurman RJ; Cope L; Pohl G; Samuels Y; Velculescu VE; Wang TL; Shih IeM
Cancer Biol Ther; 2006 Jul; 5(7):779-85. PubMed ID: 16721043
[TBL] [Abstract][Full Text] [Related]
32. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform.
Tsuda H; Birrer MJ; Ito YM; Ohashi Y; Lin M; Lee C; Wong WH; Rao PH; Lau CC; Berkowitz RS; Wong KK; Mok SC
Cancer Genet Cytogenet; 2004 Dec; 155(2):97-107. PubMed ID: 15571795
[TBL] [Abstract][Full Text] [Related]
33. Comparative study of primary and recurrent ovarian serous carcinomas: comparative genomic hybridization analysis with a potential application for prognosis.
Hu J; Khanna V; Jones MW; Surti U
Gynecol Oncol; 2003 Jun; 89(3):369-75. PubMed ID: 12798697
[TBL] [Abstract][Full Text] [Related]
34. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
[TBL] [Abstract][Full Text] [Related]
35. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.
Lohneis P; Darb-Esfahani S; Dietel M; Braicu I; Sehouli J; Arsenic R
Anticancer Res; 2015 Nov; 35(11):6329-34. PubMed ID: 26504072
[TBL] [Abstract][Full Text] [Related]
36. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
37. Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.
Osterberg L; Levan K; Partheen K; Delle U; Olsson B; Sundfeldt K; Horvath G
BMC Cancer; 2009 Oct; 9():368. PubMed ID: 19835627
[TBL] [Abstract][Full Text] [Related]
38. SOX2 expression and prognostic significance in ovarian carcinoma.
Pham DL; Scheble V; Bareiss P; Fischer A; Beschorner C; Adam A; Bachmann C; Neubauer H; Boesmueller H; Kanz L; Wallwiener D; Fend F; Lengerke C; Perner S; Fehm T; Staebler A
Int J Gynecol Pathol; 2013 Jul; 32(4):358-67. PubMed ID: 23722508
[TBL] [Abstract][Full Text] [Related]
39. Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas.
Tapper J; Bützow R; Wahlström T; Seppälä M; Knuutila S
Br J Cancer; 1997; 75(12):1782-7. PubMed ID: 9192982
[TBL] [Abstract][Full Text] [Related]
40. [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization].
Zhong M; Li J; Ding YQ; Song LL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec; 23(6):665-7. PubMed ID: 17160949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
